ESG Telegraph
  • Home
  • Latest News
  • Environment
  • Companies
  • Investors
  • Governance
  • Markets
  • Social
  • Regulators
  • Sustainable Finance
Featured Posts
    • Companies
    European office market faces biggest test since financial crisis
    • August 15, 2022
    • Markets
    Uniper drops coal case as tensions rise over treaty on fossil fuel projects
    • August 15, 2022
    • Latest News
    Stock markets subdued after weaker than expected Chinese data
    • August 15, 2022
    • Companies
    Vanguard active funds suffer bloodiest first-half on record
    • August 15, 2022
    • Markets
    Why the Fed might be at ‘neutral’ already on monetary policy
    • August 15, 2022
Featured Categories
Belarussia
View Posts
Companies
View Posts
Energy
View Posts
Environment
View Posts
Food
View Posts
Governance
View Posts
Health
View Posts
Investors
View Posts
Latest News
View Posts
Markets
View Posts
Potash
View Posts
Regulators
View Posts
Russsia
View Posts
Social
View Posts
Supply Chain
View Posts
Sustainable Finance
View Posts
Technology
View Posts
Uncategorized
View Posts
ESG Telegraph ESG Telegraph
7K
9K
4K
1K
ESG Telegraph ESG Telegraph
  • Home
  • Latest News
  • Environment
  • Companies
  • Investors
  • Governance
  • Markets
  • Social
  • Regulators
  • Sustainable Finance
  • Companies

Altos Labs insists mission is to improve lives not cheat death

  • January 23, 2022
  • Staff
Total
0
Shares
0
0
0

Altos Labs launched with the most funding of any biotech start-up ever, a board packed with Nobel Prize winners — and high expectations that it was trying to defeat death.

But the top scientists behind the new venture, which last week revealed it had raised $3bn from investors, insist they plan to reverse disease so people can live healthier for longer rather than chasing a sci-fi vision of helping some live forever.

Rick Klausner, chief scientific officer and former director of the US National Cancer Institute, told the Financial Times the company was aiming to be the “Bell Labs” of biology, a reference to the innovative research and development unit behind technologies such as the transistor.

Altos Labs will investigate how to rejuvenate cells under pressure from stresses including genetic abnormalities, injuries or ageing. By reprogramming cells, it could find medicines that treat many diseases at once, potentially disrupting the business of drug discovery.

Klausner said early scientific papers on the rejuvenating cells were greeted with “tremendous scepticism”, suggesting it was “too good to be true”. But he added that those findings had now been replicated by many other labs and in other circumstances, and had proved to be robust.

Altos Labs kept its mission under wraps until last week when it revealed its mammoth fundraising from unnamed investors and announced it had poached GlaxoSmithKline’s chief scientific officer Hal Barron to be chief executive.

Reports ahead of its launch claimed backers include billionaires Jeff Bezos and Yuri Milner, and speculated that it would be the latest of a series of start-ups trying to use new anti-ageing science to increase lifespan.

However, Hans Bishop, the new president of Altos who worked with Klausner on oncology start-ups including Grail and Juno Therapeutics, said its focus was on increasing “healthspan”, and that any extension in longevity would be “an accidental consequence”.

He said that while a cure for cancer would only add a few years to the average lifespan, the impact would be far greater.

“Our goal is to focus on this huge problem in society that many years of people’s lives are afflicted by chronic diseases that destroy their quality of life . . . productivity and income at a huge cost to society,” he said. “If we can reverse those diseases, we generate an enormous benefit.”

Altos Labs will operate out of two hubs in California and one in the UK’s Cambridge, with significant research done in Japan, where Nobel Prize winner Shinya Yamanaka pioneered rejuvenation programming. Yamanaka will oversee research in Japan and serve as an adviser, while Nobel laureates Jennifer Doudna, Frances Arnold and David Baltimore will join the board.

The company aims to combine top scientists from academia with a mission to make medicines, even though most of the research is still at an early stage in mouse models.

Klausner, who came up with the initial idea over a series of video meetings during 2020, said the company had now realised it could move into clinical trials earlier than expected.

“I think we’re going to move into humans as quickly as possible,” he said.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
You May Also Like
Read More
  • Companies

European office market faces biggest test since financial crisis

  • Staff
  • August 15, 2022
Read More
  • Companies

Vanguard active funds suffer bloodiest first-half on record

  • Staff
  • August 15, 2022
Read More
  • Companies

Digital advertising: Apple takes bigger bite of new business

  • Staff
  • August 15, 2022
Read More
  • Companies

Climate and crypto fraught with challenges for regulators 

  • Staff
  • August 15, 2022
Read More
  • Companies

FirstFT: European office market’s big test

  • Staff
  • August 15, 2022
Read More
  • Companies

How female founders are challenging the funding gap

  • Staff
  • August 15, 2022
Read More
  • Companies

UK employers could be forced to pay down pension deficits

  • Staff
  • August 15, 2022
Read More
  • Companies

Afghan roads once menaced by the Taliban are now safer. . . for some

  • Staff
  • August 15, 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Featured Posts
  • 1
    European office market faces biggest test since financial crisis
    • August 15, 2022
  • 2
    Uniper drops coal case as tensions rise over treaty on fossil fuel projects
    • August 15, 2022
  • 3
    Stock markets subdued after weaker than expected Chinese data
    • August 15, 2022
  • 4
    Vanguard active funds suffer bloodiest first-half on record
    • August 15, 2022
  • 5
    Why the Fed might be at ‘neutral’ already on monetary policy
    • August 15, 2022
Recent Posts
  • Rio Tinto rebuffed in plan to take control of Mongolia copper project
    • August 15, 2022
  • Digital advertising: Apple takes bigger bite of new business
    • August 15, 2022
  • At 75, India is finally ready to join the global party
    • August 15, 2022

Sign Up for Our Newsletters

Subscribe now to our newsletter

ESG Telegraph
  • Home
  • Privacy Policy
  • Guest Post
  • Contact

Input your search keywords and press Enter.